WUXI BIOLOGICS Aktie

 

SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has......

UBS research report indicated that WUXI BIO (02269.HK) met expectations with its performance in the second half of last year, with revenue increasing by 17.2% year-on-year to RMB11.8 billion (same below), and profit attributable to shareholders rising by 38.3% year-on-year to RMB2.6 billion. The gross profit margin improved by 5......

SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a transformative leap in operational......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps) EBITDA rose 38.1% YoY and IFRS net profit increased 45.3% YoY;......

WUXI BIO (02269.HK) announced its full-year results for the year ended December 31, 2025. Revenue reached RMB21.79 billion, a YoY rise of 16.7%. It recorded net profit of RMB4.908 billion, a YoY hike of 46.3%, with an EPS of RMB1.22. Gross profit added by 30.9% YoY to RMB10.019 billion, and the gross profit margin improved by 5%......

SHANGHAI, March 21, 2026 /PRNewswire/ -- On the occasion of World Water Day, WuXi Biologics reaffirms its commitment to sustainability through responsible operations and efficient, circular water‑use practices that reduce environmental impact. WuXi Biologics has been named to the CDP......

SINGAPORE, March 12, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma......

WILMINGTON, Del., March 12, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today......

SHANGHAI, March 1, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Global Sustainability Yearbook 2026 ("Yearbook") in recognition of its strong performance in......

As AI technology continues to develop, investors are shifting their focus from "AI enabling industries" to "AI disintermediating middlemen", CLSA said in a research report. For CRO/ CDMO, AI is expected to have a clearer net positive for integrated CRDMO platforms. In contrast, the internal adoption of AI by ......

WUXI BIO (02269.HK) and WUXI XDC (02268.HK) stumbled by approx. 7% and 8% on Thursday (26th), while Hong Kong-listed CRO/CDMO companies lost by about 2-to 9% overall, CLSA released a research report saying. The broker believed that this decline is not driven by fundamentals but is more likely largely positioning and capital flow......

CANBRIDGE-B (01228.HK) announced the placement of 84.0336 million shares (around 14.12% of the enlarged share capital) to WuXi Biologics HealthCare Venture, a subsidiary of WUXI BIO (02269.HK), at a price of HKD2.38 per share, a 14.7% discount to the closing price of HKD2.79 on February 13.The total fundraising from this placeme......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

According to a BofA Securities research report, WUXI BIO (02269.HK) has issued a positive profit alert, estimating its 2025 revenue to have grown by 16.7% YoY to RMB21.8 billion, aligning with the broker's expectations.This performance is attributable to a record number of WUXI BIO's new projects and expanded service off......

WUXI BIO (02269.HK) announced a positive profit alert projecting its 2025 revenue to grow by 16.7% YoY to RMB21.8 billion, slightly above the market consensus of RMB21.5 billion, according to Nomura's research report. Gross margin is expected to improve by 5 ppts YoY to 46%, also exceeding the market expectation of 43%. Net ......

At midday close, HSI dropped 242 pts or 0.9% to 27,023. HSTI dropped 92 pts or 1.7% to 5,407. HSCEI fell 89 pts or 1.0% to 9,178.Active Heavyweights:MEITUAN (03690.HK) closed at $85.15, down 4.2%TENCENT (00700.HK) closed at $533.5, down 2.6%BABA (09988.HK) closed at $156.7, down 2.1%XIAOMI (01810.HK) closed at $36.76, down 0.9%H......

SUZHOU, China, Feb. 11, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that it has received Good Manufacturing Practices (GMP) certification for its fill and......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Morgan Stanley released a research report predicting that the share price of WUXI BIO (02269.HK) will rise in the next 45 days, with a probability for the scenario estimated between 70% and 80%. The Company recently issued a positive profit alert, with management guidance at an event that growth will accelerate in FY2026, a 16% ......